ARCHIVES

FDA Discloses Responses, Toxicities For Burzynski’s “Antineoplastons”

This article is from The Cancer Letter archive.

Vol. 24 No. 16 | April 24, 1998

Download PDF Visit The Full Archive

Related Articles

ORI Final Findings Of Scientific Misconduct

September 16, 1994

Clolar Approved for Pediatric Refractory/Relapsed ALL

January 28, 2005

NCCS Networker Volume 2 Issue 4, Fall 1988

September 13, 1988

Friends Of Cancer Research Plan September Launch

August 9, 1996

Skin Cancer Screens Find “Extraordinary High” Rates

September 20, 1985

Scientists Lose Credibility When “Fire Alarm” Pulled Too Early, ACS’s Brawley Says.

August 1, 2008